Bristol Myers Squibb said it has received positive opinion for Opdivo, its treatment of esophageal or gastroesophageal junction cancer, from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
The company on Friday said the European Commission, which has the authority to approve medicines, will now review the recommendation.
The committee's positive opinion is based on a phase three trial of Opdivo, Bristol Myers Squibb said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.